Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data
1. Viking Therapeutics shares dropped over 30% after disappointing trial data. 2. Data suggests VK2735 may not compete with Eli Lilly and Novo Nordisk drugs. 3. Viking's pill showed inferior results in weight loss compared to competitor drugs. 4. High discontinuation rates of Viking's treatment raise concerns for investors. 5. Gastrointestinal side effects reported more frequently in Viking's trial.